immune thrombocytopenia

Roxifiban acetate(DMP 754 acetate) is a potent GP IIb IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.

Eltrombopag (SB-497115-GR), an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity, binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110).

Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active small-molecule, nonpeptide thrombopoietin receptor agonist that stimulates megakaryopoiesis. It binds to and activates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), promoting the proliferation and differentiation of megakaryocytic cells and enhancing platelet production.

Sovleplenib (HMPL523) is an orally available, selective and potent inhibitor of the splenic tyrosine kinase SYK with an IC50 of 25 nM.Sovleplenib has antitumor activity and may be used in studies of immune thrombocytopenia (ITP).

KB-208 is a phagocytosis inhibitor that enhances immune thrombocytopenia (ITP) in mouse models at a dosage of 1 mg kg. It does not alter other blood parameters or increase serum toxicity biomarkers and is applicable for research in the field of immunology.

Hetrombopag is a potent agonist of the thrombopoietin receptor. Hetrombopag is well tolerated and has a controlled safety profile. hetrombopag has potential for studies in immune thrombocytopenia.